This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
PharmaPipelines: strategic analysis and conclusions 2006. Lehman Brothers, 2006 Sep 15
Incretin-targeting technologies for type 2 diabetes: dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 analogs. Pharma ceutical & Diagnostic Innovation 2006; 4 (7): 3–7
About this article
Cite this article
Brakes Put On Brandname Pharmaceuticals. Pharmaceutical & Diagnostic Innovation 4, 7–10 (2006). https://doi.org/10.1007/BF03257110